Jacobson Center for Clinical & Translational Research

Main Menu

/research/

Additional Information

 

Contact Us

Cardiology Research

Study Title: Zilver® PTX® V: Drug-Eluting Peripheral Stent Post-Approval Study. (Identifier: NCT01901289)

Study Purpose: The Zilver® PTX® V Clinical Study is a post-market clinical trial required by the US FDA to provide continued evaluation of the safety and effectiveness of the Zilver PTX Drug-Eluting Peripheral Stent in treatment of narrowing of the femoropopliteal arteries.

Principal Investigator: Mark Burket, M.D.

Study Coordinator: Jill Sholl, RN, for more information, please contact 419.383.3853.


Study Title: Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Ularitide (Urodilatin) Intravenous Infusion in Patients Suffering From Acute Decompensated Heart Failure. (Identifier: NCT01661634)

Study Purpose: The purpose of this study is to evaluate the efficacy and safety of a continuous intravenous (IV) ularitide infusion on the clinical status and outcome of patients with acute decompensated heart failure (ADHF).

Principal Investigator: Samer Khouri, M.D.

Study Coordinator: Jill Sholl, RN, for more information, please contact 419.383.3853.


Study Title: Lutonix® Drug coated Balloon vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis (SFA ISR). (Identifier: NCT02063672)

Study Purpose: To assess the safety and efficacy of the Lutonix Drug Coated Balloon for treatment of femoropopliteal artery (SFA) in-stent restenosis (ISR).

Principal Investigator: Mark Burket, M.D.

Study Coordinator: Jill Sholl, RN, for more information, please contact 419.383.3853.


Study Title:  A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR Added-on to treprostinil, inhaled (Tyvaso (r)) in Subjects with Pulmonary Arterial Hypertension

Study Purpose: Patients new to Tyvaso, will enter a run-in period on inhaled treprostinil until 90 days of experience is achieved to ensure drug tolerability before enrolling in the study.

Principal Investigator: George Moukarbel, MD

Study Coordinator: Chris Eisenhauer, RN BSN, for more information, please contact 419.383.3853

Last Updated: 1/30/15